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Genetic Determinants Predicting Efﬁcacy of
Glucose-Lowering Drugs?
A long way to go …
I
n this issue of Diabetes Care, Sathanan-
than et al. (1) report differences in the
insulinotropic response to exogenous
glucagon-like peptide-1 (GLP-1) in
healthy volunteers, depending on the
presence or absence of certain common
polymorphisms of the GLP-1 receptor
gene. This study suggests that individuals
may variably respond to GLP-1, depend-
ing on the presence or absence of minor
alleles characterized by single nucleotide
polymorphisms. The authors suggest that
the insulinotropic activity of GLP-1, as
studied with the present protocol, may
predict a better or worse clinical response
to incretin-based medications (GLP-1 re-
ceptor agonists or incretin mimetics and
inhibitors of dipeptidyl peptidase-4
[DPP-4], so-called incretin enhancers)
and thus may help select a glucose-
lowering drug tailored to the individual
needs of a given patient.
Guidelines usually present a simpli-
ﬁed ﬂowchart to suggest a uniform ap-
proachtothetreatmentoftype2diabetes,
starting with lifestyle changes aiming at a
healthier diet, calorie restriction in obese
patients, and physical activity to improve
ﬁtness and reduce the degree of insulin
resistance (2,3). Early in the course of
type 2 diabetes, metformin is rather uni-
formly recommended (2,3), although
many other glucose-lowering agents have
been approved for use as a single agent.
When metformin alone fails to secure ad-
equate glycemic control, the choice in-
cludes sulfonylureas, meglitinides,
thiazolidinediones, -glucosidase inhibi-
tors, insulin, and the incretin-based med-
ications, GLP-1 receptor agonists, and
DPP-4 inhibitors (3). There is no clear
uniform recommendation of any of these
agents to be preferentially added to met-
formintreatment.Today,thechoiceisleft
to the individual recommendation of a
physician practicing the “art of medicine”
bybeingguidedbythedrugs’proﬁlesand
by individual characteristics of a given
patient (e.g., his or her desire to lose
weight), and patients may utter prefer-
ences after having been fully informed
about the broad choice of agents. Costs
may also be an important determinant of
thischoice.Onlyforsomecircumscribed,
rare conditions (diabetes as a result of au-
tosomal dominant traits, e.g., those lead-
ing to maturity-onset diabetes of the
young type 3 [4], or as a result of muta-
tions in the potassium channel Kir 6.2
[5]), genetic characterization has been
shown to suggest therapies (in this case
sulfonylureas) that have obvious advan-
tages over alternative treatment choices
(6–9).
For average type 2 diabetic patients,
two reasons preclude simpler treatment
algorithms making use of a more re-
stricted choice of agents to be used at
some stage during the disease: 1) the
growing number of medication classes
available for the treatment of type 2 dia-
betes (3) and 2) the lack of proven supe-
riority of any potential agent over other
candidates for the general population of
type 2 diabetic patients (2). Clinical char-
acteristics (such as BMI, waist circumfer-
ence, known diabetes duration, and even
laboratory values such as C-peptide or
homeostasis model assessment of -cell
function indexes) have largely disap-
pointedaspredictorsofclinicalresponses
toantidiabeticmedicationsofinterest.On
top of these difﬁculties, most clinical
studies indicate that a great proportion of
patients, even if treated with the most po-
tent available agents, will not successfully
control their glycemia to the degree rec-
ommended by guidelines (e.g., achieving
an A1C value 7.0%), indicating a sub-
stantial proportion of “nonresponders” to
almost all available treatments (10–12).
Withrespectto“nonresponse”toglu-
cose-lowering treatments, an important
distinction has to be made: although clin-
ically a responder will achieve a certain
reduction in A1C or reach a given A1C
target by the end of such clinical trials
(usually lasting 6–12 months), too many
variables (eating habits, adherence to reg-
ular exercise, etc.) will determine the out-
come,sothatnotreachinganyofthegoals
cannotaloneandwithcertaintyberelated
to the effectiveness of the drug in ques-
tion. Nevertheless, a mechanistic nonre-
sponse may exist rooted in the patients’
probability to respond to any drug based
on its mechanism of actions, perhaps me-
diatedbyvariationsinthestructuresused
to elicit response. This may, as a simple
example, be related to receptor outﬁts
that play a role in generating responses to
the drug in question. In this respect, the
study by Sathananthan et al. (1) is one of
few examples plausibly showing that
genetically different GLP-1 receptors
determine some heterogeneity in the in-
sulinotropic effectiveness of GLP-1. Pre-
vious studies have already suggested that
mutations or variations in the nucleotide
sequence of the GLP-1 receptor gene de-
termine the magnitude of intracellular
postreceptor signaling (13–16). These
mutationswererare,butthepresentlyde-
scribed polymorphisms are common and
potentially affect many subjects.
Two mechanisms can be responsible:
1) the GLP-1 receptor triggers more or
less generation of cAMP compared with
the major allele, which is found in the
larger proportion of a population, so that
the acute insulinotropic effect is modi-
ﬁed; or 2) the variation in GLP-1 receptor
activityhasledtoanaltered-cellmassor
function, since GLP-1 receptor signaling
is coupled to the induction of neogenesis
orproliferationof-cells,andreducesap-
optosis, at least in some cell lines and in
rodents (17,18). In addition, the normal
cellular organization of islets appears to
depend on GLP-1 receptor signaling
(19). This, in turn, may determine islet
function in more general terms, such as
responses to glucose and other secreta-
gogues, and not speciﬁcally the respon-
siveness to GLP-1 alone. The latter is
suggested by the fact that the heterozy-
gotic rs3765467 polymorphism aug-
ments the insulin secretory response to a
hyperglycemic clamp alone as well as to
exogenous GLP-1 in the present study
(1). Responses to GLP-1 may have rele-
vance in predicting the clinical effective-
ness of GLP-1 receptor agonists and
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type 2 diabetes. To demonstrate this, it
will be necessary to repeat the current ex-
perimentsinpatientswithdiabetesandto
correlate the in vitro test results with clin-
ical responses and the likelihood of
achieving glycemic targets. It may well be
that the -cell deﬁciency and altered
function generally characteristic of type 2
diabetes may preclude the demonstration
of subtle differences in the response to
exogenous GLP-1 in such a population.
In the long run, multiple genetic
traits, such as polymorphisms related to
TCF7L2(21–24),FOXO1(25),andWFS1
(26); potassium channels associated with
sulfonylurea receptors (5); and many
more aspects of -cell mass and function,
including parameters related to insulin
resistance, may as a whole help predict
the individual response to speciﬁc glu-
cose-lowering treatments. This could be
of great help in recommending the best
possible agent for an individual (27),
improving the likelihood of treatment
success, and justifying higher costs, if
cheaper drugs can be predicted to fail in a
given patient. But, we have to admit, this
willrequireasubstantialeffortintermsof
systematic research. There will be no
short-term success. Studies such as the
one by Sathananthan et al. (1) raise some
optimism that eventually this vision will
come true.
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